Sponsor
- Home
- Your Messages
-
Smartest Doc
Test your clinical knowledge against other physicians in the USA by taking our FREE daily quiz!
We invite you to take the "Renal cell carcinoma Quiz"
Current Top Players:
1) Dr. Sandeep Chunduri
2) Dr. Hassan Ghazal
3) Dr. Amer Khouri
>> Live LeaderboardNew! PHYSICIAN REVIEW
Assess your general knowledge at the topic level with your personalized scorecard.
Thousands of multiple-choice questions pinpoint your areas of expertise and prep you for exams.
- Physician Jobs (511)
- More
- Other Specialty
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib
European Journal of Nuclear Medicine & Molecular Imaging, 05/07/2012
Kobe C et al. – Early and late residual 18F–fluorodeoxyglucose (FDG) uptake, measured using different quantitative SUV parameters, are predictive factors for short–term outcome in patients with advanced non–small–cell lung cancer (NSCLC) treated with erlotinib. Additionally, low residual FDG and 18F–fluorothymidine (FLT) uptake early and late in the course of erlotinib treatment is associated with improved progression–free survival (PFS).
Register now to view all the MDLinx contents (FREE)!
- Stay current on the latest literature, research and clinical news
- Get special communications and offers from MDLinx and our sponsors
- Receive invitations to paid market research
Login
Sponsor
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close
Sponsor